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Knowledge of a disease pathway represents in general a prerequisite for a more precise definition of disease prognosis as well as a valuable hint to provide the patient with the most appropriate therapeutic regimen. During an acute myocarditis caused by enterovirus (EV) several mechanisms of myocyte damage can actually be recognized including ( Figure 1 ): (a) the induction of an inflammatory reaction to the infectious agent; (b) the release of destructive proteases from the host; and (g) the activation of intracellular apoptotic pathways. In particular, EV myocardial inflammation (a), even through stimulation of Toll-like receptors, 1 is always associated with biological events such as as release of cytokines, complement (mainly components C8 -C9) and T lymphocytebound perforins that jeopardize cell structure and function as well as the integrity of the interstitial compartment. 2 Additionally, in a limited cohort of patients with a human leucocyte antigen (HLA) system capable of presenting on the cardiomyocyte membrane a segregated autoantigen (such as myosin) or newly formed virus-shared antigens (antigenic mimicry), 3 an autoimmune process can be activated leading to a chronic myocardial inflammation and progressive heart failure. Protease 2A (b) is a well known product of Coxsackievirus B which is able to cleave the cytoskeleton protein dystrophin and disconnect myofilaments from the sarcolemma membrane, inducing a progressive degradation and loss of contractile elements. 4 The study of Vénteo et al. 5 focuses on mitochondrial apoptotic pathways (g) activated in cardiomyocytes during an acute EV myocarditis compared with healthy controls. The authors reveal that in patients with EV-associated acute myocarditis, cardiac VP1 expression appeared to be high. Likewise in patients with EV-associated acute myocarditis, apoptotic cardiomyocytes were detected in a significantly higher number than in those with EV-negative myocarditis or in controls, indicating a direct cytopathic effect of the viral infection leading to cardiac cell death through apoptosis. Similar results were achieved by investigating the cytosolic/mitochondrial cytochrome c concentration and level of active caspase-9 which was significantly decreased in EV compared with non-EV-related myocarditis patients. On the basis of this evidence, the authors conclude that EV cardiac replication activity measured by expression of VP1 EV protein within the myocardium induces a differential modulation of the cardiomyocyte mitochondrial apoptotic pathway in patients with active myocarditis compared with non-viral myocarditis, which can be in part responsible for the progression from EV-related myocarditis to end-stage dilated cardiomyopathy (DCM). The observation in EV-infected myocardial tissue of a compensatory upregulation of the anti-apoptotic Bax with an increase of the Bax/Bcl2 mRNA ratio seems to confirm the authors' statements. Ventéo's work has the merit of recognizing a viral-mediated activation of mitochondrial apoptotic pathway in patients with EV myocardial infection. Quantification of its impact on loss of cardiac function particularly in comparison with inflammation (a) and the myofibrillolysis (b) pathway is, however, not available. In addition, its role in the progression of acute EV myocarditis to endstage EV DCM is not conclusive. Quantitative evaluation of a specific role for the a, b, and g pathways respectively, on the impairment of cardiac function could be theoretically obtained by studying sequential endomyocardial biopsies of patients with acute EV myocardial infection having a different outcome. Nevertheless, Ventéo's study still has a remarkable investigational interest and expands the possible targets of therapeutic interventions. In particular, acute EV myocarditis can be a life-threatening condition where there is actually a common agreement only for pharmacological [carvedilol, angotensin-converting enzyme (ACE) inhibitors, diuretics, digitalis, vasodilators] and mechanical (left ventricular assist device) supportive therapy. High dose immunoglobulins (1 g/kg of body weight) are specifically recommended in children and immune-depressed patients with active viral replication, 6 while immunoadsorption therapy has not yet produced conclusive results. 7 Antiviral therapy targeting the Coxsackievirus -adenovirus
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receptor is still experimental. 8 Administration of antiviral drugs has not yet provided encouraging results, and finally use of b-interferon seems to be contraindicated since in an acute viral myocarditis it could enhance myocardial inflammation. 9 In this context, the report by Vénteo et al. raises the possibility that inhibition of cell apoptosis may provide a novel target for treatment directed against acute and fulminant EV myocarditis. Indeed, recently, it has been demonstrated that drotrecogin alpha, which is a treatment in sepsis-induced multiple organ failure, can induce a significant decrease of both the Bax/Bcl-2 and Bax/Bcl-xl ratios. 10 This suggests the potential utility of this new drug in 
